Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE1
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Afatinib Osimertinib Sequencing NIS
- Status
- COMPLETED
- Phase
- N/A
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
- Status
- COMPLETED
- Phase
- N/A
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Status
- RECRUITING
- Phase
- PHASE2
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
- Status
- COMPLETED
- Phase
- N/A
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2